The new German evidence-based guideline on diffuse large B-cell lymphoma—key aspects for radiation oncologists
暂无分享,去创建一个
H. Eich | G. Lenz | K. Herfarth | P. Borchmann | G. Held | H. Schmidberger | Christian Berdel | M. Ernst | M. Oertel | C. Berdel
[1] G. Kanas,et al. Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020–2025 , 2021, Leukemia & lymphoma.
[2] Prashanth Rawla,et al. Epidemiology of Non-Hodgkin’s Lymphoma , 2021, Medical sciences.
[3] H. Kang,et al. Pattern of failure and optimal treatment strategy for primary gastric diffuse large B-cell lymphoma treated with R-CHOP chemotherapy , 2020, PloS one.
[4] D. Scott,et al. Long-Term Results of PET-Guided Radiation in Advanced-Stage Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP. , 2020, Blood.
[5] H. Eich,et al. Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines. , 2020, International journal of radiation oncology, biology, physics.
[6] H. Eich,et al. The Optimal Use of Imaging in Radiation Therapy for Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG). , 2019, International journal of radiation oncology, biology, physics.
[7] M. Ziepert,et al. Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL/GLA. , 2018 .
[8] A. Ng,et al. Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. , 2018, International journal of radiation oncology, biology, physics.
[9] M. Ziepert,et al. Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL. , 2017 .
[10] M. Gonen,et al. A prospective study of ¹⁸FDG-PET with CT coregistration for radiation treatment planning of lymphomas and other hematologic malignancies. , 2014, International journal of radiation oncology, biology, physics.
[11] A. Ng,et al. Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. , 2014, International journal of radiation oncology, biology, physics.
[12] C. Rübe,et al. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] C. Rübe,et al. Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] David Cunningham,et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles , 2013, The Lancet.
[15] A. López-Guillermo,et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. , 2011, The Lancet. Oncology.
[16] P. Hoskin,et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[17] Markus Loeffler,et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). , 2008, The Lancet. Oncology.
[18] Kihyun Kim,et al. Consideration of aggressive therapeutic strategies for primary testicular lymphoma , 2007, American journal of hematology.
[19] F. Cavalli,et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] R. Mirimanoff,et al. Outcome and patterns of failure in testicular lymphoma: a multicenter Rare Cancer Network study. , 2002, International journal of radiation oncology, biology, physics.
[21] J. Chan,et al. Relationship between high-grade lymphoma and low-grade B-cell mucosa-associated lymphoid tissue lymphoma (MALToma) of the stomach. , 1990, The American journal of pathology.